ALNYLAM PHARMACEUTICALS INC (ALNY)
US02043Q1076 - Common Stock
ALNY gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. While ALNY seems to be doing ok healthwise, there are quite some concerns on its profitability. ALNY is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ALNY had negative earnings in the past year.
In the past year ALNY had a positive cash flow from operations.
ALNY had negative earnings in each of the past 5 years.
ALNY had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of ALNY (-11.49%) is better than 88.87% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.49% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-22.27%
ROA(5y)-25.8%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of ALNY (83.02%) is better than 88.53% of its industry peers.
ALNY's Gross Margin has declined in the last couple of years.
ALNY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.02% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.45%
GM growth 5Y-3.18%
2. Health
2.1 Basic Checks
ALNY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ALNY has been increased compared to 1 year ago.
The number of shares outstanding for ALNY has been increased compared to 5 years ago.
Compared to 1 year ago, ALNY has an improved debt to assets ratio.
2.2 Solvency
ALNY has an Altman-Z score of 0.98. This is a bad value and indicates that ALNY is not financially healthy and even has some risk of bankruptcy.
ALNY has a Altman-Z score of 0.98. This is in the better half of the industry: ALNY outperforms 66.27% of its industry peers.
ALNY has a debt to FCF ratio of 24.34. This is a negative value and a sign of low solvency as ALNY would need 24.34 years to pay back of all of its debts.
ALNY has a better Debt to FCF ratio (24.34) than 94.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 24.34 | ||
| Altman-Z | 0.98 |
ROIC/WACCN/A
WACC8.93%
2.3 Liquidity
ALNY has a Current Ratio of 3.08. This indicates that ALNY is financially healthy and has no problem in meeting its short term obligations.
ALNY has a Current ratio of 3.08. This is in the lower half of the industry: ALNY underperforms 65.58% of its industry peers.
A Quick Ratio of 2.99 indicates that ALNY has no problem at all paying its short term obligations.
ALNY has a Quick ratio of 2.99. This is in the lower half of the industry: ALNY underperforms 65.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.08 | ||
| Quick Ratio | 2.99 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.89% over the past year.
ALNY shows a strong growth in Revenue. In the last year, the Revenue has grown by 76.24%.
The Revenue has been growing by 89.46% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)58.89%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q34.52%
Revenue 1Y (TTM)76.24%
Revenue growth 3Y54.8%
Revenue growth 5Y89.46%
Revenue growth Q2Q31.26%
3.2 Future
ALNY is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 46.07% yearly.
ALNY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.71% yearly.
EPS Next Y-19.86%
EPS Next 2Y22.28%
EPS Next 3Y38.41%
EPS Next 5Y46.07%
Revenue Next Year1.07%
Revenue Next 2Y12.81%
Revenue Next 3Y19.98%
Revenue Next 5Y24.71%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ALNY reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALNY. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
93.66% of the companies in the same industry are more expensive than ALNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 431.46 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
ALNY's earnings are expected to grow with 38.41% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.28%
EPS Next 3Y38.41%
5. Dividend
5.1 Amount
ALNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALNYLAM PHARMACEUTICALS INC
NASDAQ:ALNY (4/25/2024, 7:00:00 PM)
After market: 143.71 0 (0%)143.71
-0.09 (-0.06%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap18.10B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.49% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 83.02% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.08 | ||
| Quick Ratio | 2.99 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)58.89%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-19.86%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)76.24%
Revenue growth 3Y54.8%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y